These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3321822)

  • 1. [CA 19-9 and cancer of the pancreas. Critical review of the literature].
    Delcourt A
    Acta Gastroenterol Belg; 1987; 50(1):1-8. PubMed ID: 3321822
    [No Abstract]   [Full Text] [Related]  

  • 2. [The contribution of CA 19-9 in the differential diagnosis between chronic pancreatitis and cancer of the pancreas].
    Van Gossum M; Delanghe A; Gerard M; Delcourt A; Deltenre M
    Acta Gastroenterol Belg; 1987; 50(1):91-4. PubMed ID: 3480672
    [No Abstract]   [Full Text] [Related]  

  • 3. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
    Klapdor R; Greten H
    Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
    [No Abstract]   [Full Text] [Related]  

  • 4. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
    Röthlin M; Metzger U; Joller H; Largiadèr F
    Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Attention to CA 19.9 in alcoholics. Apropos of a case].
    Giovannini M; Penalvert F; Maillot A; Escoffier JM; Botta D; Gauthier A
    Ann Gastroenterol Hepatol (Paris); 1987 Dec; 23(7):393. PubMed ID: 3481241
    [No Abstract]   [Full Text] [Related]  

  • 7. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
    Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of the determination of serum CA19.9 in patients with tumor or non-tumor pancreatopathies].
    Encabo G; Ruibal A; Gefaell R; Martínez Miralles E; Salgado A; Fernández Llamazares J
    Med Clin (Barc); 1984 Mar; 82(12):560-1. PubMed ID: 6588282
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
    Safi F; Büchler M; Schenkluhn B; Beger HG
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbohydrate antigen (CA 19-9)--a valuable tumor marker of pancreatic cancer.
    Lin JT; Wang TH; Sung JL; Chen DS
    Taiwan Yi Xue Hui Za Zhi; 1985 Jul; 84(7):828-35. PubMed ID: 3864924
    [No Abstract]   [Full Text] [Related]  

  • 11. Pancreatic oncofoetal antigen in pancreatic cancer.
    Hobbs JR; Branfoot AC; Knapp ML
    Practitioner; 1980 Oct; 224(1348):1023-7. PubMed ID: 7220429
    [No Abstract]   [Full Text] [Related]  

  • 12. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
    Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
    Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of carbohydrate antigens 19-9 and 12-5 in patients with pancreatic cancer.
    Pasquali C; Sperti C; D'Andrea AA; Bonadimani B; Del Favero G; Petrin P; Pedrazzoli S
    Pancreas; 1987; 2(1):34-7. PubMed ID: 3472197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential diagnosis of pancreatic cancer and chronic pancreatitis by a monoclonal antibody detecting a new cancer-associated antigen (CA 19-9).
    Malesci A; Tommasini MA; Bocchia P; Zerbi A; Beretta E; Vecchi M; Di Carlo V
    Ric Clin Lab; 1984; 14(3):303-6. PubMed ID: 6522955
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
    Ohkura H; Sakawaki T
    Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
    Staab HJ
    Acta Gastroenterol Belg; 1987; 50(1):29-35. PubMed ID: 3480668
    [No Abstract]   [Full Text] [Related]  

  • 17. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
    Heptner G; Domschke S; Schneider MU; Domschke W
    Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of CA-50 radioimmunoassay in differentiating benign and malignant pancreatic disease.
    Habib NA; Hershman MJ; Haberland F; Papp L; Wood CB; Williamson RC
    Br J Cancer; 1986 May; 53(5):697-9. PubMed ID: 3459510
    [No Abstract]   [Full Text] [Related]  

  • 19. [Diagnosis of recurrence and evaluation of the course of pancreatic cancer. Combined use of sonography and the new tumor marker CA 19-9].
    Guthoff A; Klapdor U; Klapdor R; Eichfuss HP; Dallek M; Greten H
    Dtsch Med Wochenschr; 1984 Sep; 109(37):1410-2. PubMed ID: 6383759
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
    Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O
    Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.